Scientists believe that many diseases are not only related to the external environment, but also genetic. Genetic testing can help people find out the genetic factors causing disease, so that they can adjust their lifestyles in a targeted manner to prevent or delay the occurrence of diseases. That’s why there are many DNA testing companies, each offering a different type of test. Here are some of the companies invested in developing and commercializing the DNA Testing industry. This list’s performance is calculated on an equally weighted method.

This list has performed -16.14% over the past year. By comparison, S&P BSE Sensex Index is 1.44% over the same period. The beta of this list, which is a measure of volatility, is Moderately High at 1.38. List Beta is calculated using an equally weighted average beta of the securities within this list.

List performance is calculated using an equal-weight methodology. This list is generated by scanning the web and using our algorithms to surface potentially relevant securities to the topic. The list is intended to be educational and includes securities that may be suitable for a watchlist. It is not intended for investment or trading purposes. Microsoft does not recommend using the data and information provided as the basis for making any investment decision.


PACB. Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The Company’s Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.

Pacific Biosciences of California Inc. is -15.41% over the past month and -19.12% over the past year, underperforming the S&P BSE Sensex Index by -9.40% over the past month and -20.56% over the past year.


ILMN. Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Illumina Inc. is +6.19% over the past month and -33.50% over the past year, outperforming the S&P BSE Sensex Index by +12.20% over the past month and -34.94% over the past year.


NTLA. Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin’s lymphoma.

Intellia Therapeutics Inc. is +0.42% over the past month and -41.27% over the past year, outperforming the S&P BSE Sensex Index by +6.43% over the past month and -42.71% over the past year.


SGMO. Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; TX200, its wholly owned Chimeric Antigen Receptor (CAR), engineered regulatory T cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A., and BIVV003, its zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD).

Sangamo Therapeutics Inc. is -30.62% over the past month and -63.65% over the past year, underperforming the S&P BSE Sensex Index by -24.61% over the past month and -65.09% over the past year.


EXAS. Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp. is +4.21% over the past month and +3.09% over the past year, outperforming the S&P BSE Sensex Index by +10.22% over the past month and +1.65% over the past year.

!a1zfk2:0.99,a1vh4c:0.99,a1ys77:0.99,a22up2:0.99,a1shgh:0.99,bjkr8m:0.99,a24bsm:0.99,a1mwzr:0.99,a1qcu2:0.99,a1mnrw:0.99;Pipeline;finance list details page;3adbd4bf82b2

By editor

Leave a Reply

Your email address will not be published. Required fields are marked *